Attovia Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the research and development of next-generation precision biologics for immune-mediated diseases. Headquartered in San Carlos, California, the company leverages its proprietary ATTOBODY platform—licensed from Alamar Biosciences—to engineer complex mono-, bi-, and tri-specific biologics. The platform utilizes an evolution-based high-throughput workflow to rapidly discover highly diverse therapeutic candidates. Attovia's lead product candidate, ATTO-1310, is an anti-IL-31 biologic currently in Phase 1 clinical development for the treatment of chronic pruritus of unknown origin (CPUO) and high-itch atopic dermatitis. The company's pipeline also includes ATTO-2306, a bispecific antibody targeting IL-13 and IL-31 for moderate-to-severe atopic dermatitis, and ATTO-1091, a trispecific biologic targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease (IBD). As a pre-revenue clinical-stage company, Attovia does not yet generate product sales and relies on capital raised through equity financings, including its August 2026 initial public offering, to fund its research and clinical trials.
We couldn't find any ticker for ATTO. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!